Datapoint: GSK Scores Nasal Polyps Approval for Nucala

The FDA on July 29 approved GlaxoSmithKline’s Nucala for the treatment of chronic rhinosinusitis with nasal polyps, making it the first IL-5 inhibitor in its class. The biologic will have to face off against Sanofi and Regeneron’s Dupixent, which was approved for nasal polyps in 2019. Under the pharmacy benefit, Dupixent holds preferred status (with utilization management restrictions applied in most cases) for 38% of all covered lives. Overall, it holds covered or better status for 73% of lives.

SOURCE: MMIT Analytics, as of 8/2/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 22

Datapoint: CMS Extends Medicaid Redetermination Deadline

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today